Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock

The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a second IPO application to list in Hong Kong, hoping to become the first HPV vaccine maker in the market The company was valued at around 9 billion yuan after its latest funding round By Molly Wen What started as a chance to participate in trials for an HPV 9-valent vaccine, which protects again cervical cancer, turned into something more like…

Read More »